1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
(NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.
Shares of Pfizer have been beaten severely in response to sinking sales of Comirnaty, its COVID-19 vaccine, and Paxlovid, an antiviral treatment. At its beaten-down price, it offers an eye-popping 5.9% dividend yield.
Pfizer has raised its dividend payout every year since 2009. The stock is down because COVID-19 product sales have been disappointing. Luckily, this company has enough products besides Comirnaty and Paxlovid to keep growing total sales over the long run.
Source Fool.com
Pfizer Inc. Aktie
27,88 €
-1,97 %
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 27.88 € bedeuten.
